In-vitro activity of oxymino-cephalosporins with and without sulbactam against Class A Extended-spectrum β-lactamase producing E.coli

Yıl 2011, Cilt: 1 Sayı: 03, 87 - 92, 01.09.2011

Fetiye Kolaylı Cansu Semiz Haluk Vahaboğlu

https://doi.org/10.5799/ahinjs.02.2011.03.0022

Öz

Objectives: The primary aim of this study was to determine the activities of ceftazidime and cefepime combined to sulbactam against class A extended-spectrum β lactamases (ESBLs). Materials and methods: Eight university hospitals participated to the study by submitting isolates those were recovered during a six-month period in 2010 from various clinical materials. Sulbactam was tested in two fixed concentrations of 4 mg/l and 8 mg/l. Isolates showing a fourfold or more decrease in the MIC of an oxyimino-cephalosporin with sulbactam were defined as ESBL producers. Isolates were screened for CTX-M group 1 extended-spectrum β lactamases by PCR. Results: A total of 149 ESBL-positive E.coli were studied. Isolates were uniformly susceptible to carbapenems and highly resistant to ciprofloxacin. According to CLSI breakpoints, 28% (42/149) of isolates were susceptible to ceftazidime and 32% (47/149) to cefepime. With 4 mg/L and 8 mg/L sulbactam supplement, ceftazidime susceptibility rose to 69% (103/149) and 88% (131/149), while cefepime susceptibility rose to 86 % (128/149) and 95% (141/149), respectively. PCR screening revealed that 63% (94/149) of the isolates were positive for blaCTX-M and 38% (36/94) of these were on the O25b-ST131 clone. Conclusion: Ceftazidime plus sulbactam and cefepime plus sulbactam showed remarkable activity against ESBL-positive E.coli.

Anahtar Kelimeler

Extended-spectrum β-lactamase, Escherichia coli, ceftazidime, cefepim

In-vitro activity of oxymino-cephalosporins with and without sulbactam against Class A Extended-spectrum β-lactamase producing E.coli

Öz

Anahtar Kelimeler

-

Kaynakça

• Bush K, Jacoby GA. Updated functional classification of beta- lactamases. Antimicrob Agents Chemother 2010; 54:969- 976.
• Akinci E, Vahaboglu H. Minor extended-spectrum β-lactamases. Expert Rev Anti Infect Ther 2010; 8:1251-1258.
• Coque TM, Novais A, Carattoli A et al. Dissemination of clon- ally related Escherichia coli strains expressing extended- spectrum beta-lactamase CTX-M-15. Emerg Infect Dis 2008; 14:195-200.
• Nicolas-Chanoine M, Blanco J, Leflon-Guibout V et al. Inter- continental emergence of Escherichia coli clone O25:H4- ST131 producing CTX-M-15. J Antimicrob Chemother 2008; 61:273-281.
• Marchaim D, Gottesman T, Schwartz O et al. National multi- center study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae produc- ing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2010; 54:5099-5104.
• Tumbarello M, Sanguinetti M, Montuori E et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacte- riaceae: importance of inadequate initial antimicrobial treat- ment. Antimicrob Agents Chemother 2007; 51:1987-1994.
• Clinical and Laboratory Standards Institute (2010.): Perfor- mance standards for antimicrobial susceptibility testing. Twentieth informational supplement. Document M100-S20. Wayne, PA: CLSI; 2010 CLSI.
• Clermont O, Dhanji H, Upton M et al. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother 2009; 64:274-277.
• Vahaboglu H, Budak F, Kasap M et al. High prevalence of OXA-51-type class D beta-lactamases among ceftazidime- resistant clinical isolates of Acinetobacter spp.: co-existence with OXA-58 in multiple centres. J Antimicrob Chemother 2006; 58:537-542.
• European Committee on Antimicrobial Susceptibility Testing (EUCAST). European Committee on Antimicrobial Suscepti- bility Testing (EUCAST) http://www.eucast.org [accessed 26 May 2010].
• Akhan S, Coskunkan F, Tansel O, Vahaboglu H. Conjugative resistance to tazobactam plus piperacillin among extended- spectrum beta-lactamase-producing nosocomial Klebsiella pneumoniae. Scand J Infect Dis 2001; 33:512-515.
• Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hsueh P. Comparison of CLSI 2009, CLSI 2010 and EUCAST ceph- alosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxy- toca from the SMART Global Surveillance Study. Int J Anti- microb Agents 2010; 36:293-294.
• Foulds G, Stankewich JP, Marshall DC et al. Pharmacokinet- ics of sulbactam in humans. Antimicrob Agents Chemother 1983; 23:692-699.
• Pfaller MA, Barry AL, Fuchs PC, Gerlach EH, Hardy DJ, McLaughlin JC. Comparison of fixed concentration and fixed ratio options for dilution susceptibility testing of gram-nega- tive bacilli to ampicillin and ampicillin/sulbactam. Eur J Clin Microbiol Infect Dis 1993; 12:356-362.
• Gur D, Hascelik G, Aydin N et al. Antimicrobial resistance in gram-negative hospital isolates: results of the Turkish HITIT-2 Surveillance Study of 2007. J Chemother 2009; 21:383-389.
• Azap OK, Arslan H, Serefhanoğlu K et al. Risk factors for ex- tended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 2010; 16:147-151.
• Livermore DM, Mushtaq S, Nguyen T, Warner M. Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae. Int J Antimicrob Agents 2011; 37:405-409.